Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Timothy major allergens refer to a purified preparation of the primary allergenic proteins found in Timothy grass (*Phleum pratense*) pollen, specifically Phl p 1 and Phl p 5 (historically designated as allergens 19 and 25). These proteins are utilized in allergen-specific immunotherapy (ASIT) to treat patients with grass pollen-induced allergic rhinitis (hay fever) and allergic asthma. The therapeutic approach involves the repeated subcutaneous administration of these allergens, often adsorbed to an adjuvant like aluminum hydroxide, to modulate the immune system. The mechanism of action includes the induction of peripheral T-cell tolerance (anergy), a shift from a Th2-biased to a Th1-biased immune response, and the stimulation of allergen-specific IgG4 antibodies. These IgG4 antibodies act as "blocking antibodies" that compete with IgE for allergen binding, thereby preventing the activation of mast cells and basophils and reducing allergic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on timothy major allergens.